Drug intelligence / Profile preview

QRX008

Development stage: Preclinical
Lead developer: Quoin Pharmaceuticals
Modality: Small Molecules
Administration: Unknown

Overview

QRX008 is a small molecule drug acting as an α4β1 (integrin alpha-4/beta-1) antagonist and immunomodulator. It was initially developed by Quoin Pharmaceuticals and is under preclinical development for the treatment of systemic scleroderma and potentially other immune system and skin/musculoskeletal diseases. Its mechanism of action involves antagonism of the α4β1 integrin, which may modulate immunological processes relevant to scleroderma and related pathologies[4]. No additional molecular or combination agents are included. QRX008 remains an investigational agent and has not yet advanced to clinical testing in humans.

Brand names: QRX008QRX-008QRX 008
Other names: QRX008QRX-008QRX 008

Targets

α4β1 (Integrin α4β1)

Beyond the preview

Go deeper on QRX008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QRX008.

Explore the full profile